Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

268.04
+0.84000.31%
Volume:1.34M
Turnover:358.46M
Market Cap:645.79B
PE:31.04
High:268.45
Open:266.56
Low:266.30
Close:267.20
52wk High:281.07
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.65
T/O Rate:0.06%
Dividend:5.24
Dividend Rate:1.95%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.60
PE(LYR):24.29

Loading ...

Estee Lauder Cos. Cl a Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Health Rounds: New Dye for MRI Exams Detects Lung Cancer Earlier

Reuters
·
Yesterday

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15

Dow's Nearly 300-Point Fall Led by Losses in Johnson & Johnson, Nike Stocks

Dow Jones
·
Sep 15

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Sep 15

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

Reuters
·
Sep 15

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Sep 15

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Sep 15

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14